Asset Details
Do you wish to reserve the book?
Regulation of alternative splicing of Bcl-x by BC200 contributes to breast cancer pathogenesis
Hey, we have placed the reservation for you!
By the way, why not check out events that you can attend while you pick your title.
Oops! Something went wrong.
Looks like we were not able to place the reservation. Kindly try again later.
Are you sure you want to remove the book from the shelf?
Regulation of alternative splicing of Bcl-x by BC200 contributes to breast cancer pathogenesis
Do you wish to request the book?
Regulation of alternative splicing of Bcl-x by BC200 contributes to breast cancer pathogenesis
Please be aware that the book you have requested cannot be checked out. If you would like to checkout this book, you can reserve another copy
We have requested the book for you!
Your request is successful and it will be processed during the Library working hours. Please check the status of your request in My Requests.
Oops! Something went wrong.
Looks like we were not able to place your request. Kindly try again later.
Journal Article
Regulation of alternative splicing of Bcl-x by BC200 contributes to breast cancer pathogenesis
2016
Overview
BC200 is a long non-coding RNA (lncRNA) that has been implicated in the regulation of protein synthesis, yet whether dysregulation of BC200 contributes to the pathogenesis of human diseases remains elusive. In this study, we show that BC200 is upregulated in breast cancer; among breast tumor specimens there is a higher level of BC200 in estrogen receptor (ER) positive than in ER-negative tumors. Further experiments show that activation of estrogen signaling induces expression of BC200. To determine the significance of ER-regulated BC200 expression, we knockout (KO) BC200 by CRISPR/Cas9. BC200 KO suppresses tumor cell growth
in vitro
and
in vivo
by expression of the pro-apoptotic Bcl-xS isoform. Mechanistically, BC200 contains a 17-nucleotide sequence complementary to Bcl-x pre-mRNA, which may facilitate its binding to Bcl-x pre-mRNA and recruitment of heterogeneous nuclear ribonucleoprotein (hnRNP) A2/B1, a known splicing factor. Consequently, hnRNP A2/B1 interferes with association of Bcl-x pre-mRNA with the Bcl-xS-promoting factor Sam68, leading to a blockade of Bcl-xS expression. Together, these results suggest that BC200 plays an oncogenic role in breast cancer. Thus, BC200 may serve as a prognostic marker and possible target for attenuating deregulated cell proliferation in estrogen-dependent breast cancer.
Publisher
Nature Publishing Group UK,Springer Nature B.V,Nature Publishing Group
Subject
/ Alternative Splicing - drug effects
/ Alternative Splicing - genetics
/ Biomedical and Life Sciences
/ Breast Neoplasms - pathology
/ Carcinogenesis - drug effects
/ Cell Proliferation - drug effects
/ Cell Proliferation - genetics
/ Cell Survival - drug effects
/ Female
/ Gene Expression Regulation, Neoplastic - drug effects
/ Heterogeneous-Nuclear Ribonucleoprotein Group A-B - metabolism
/ Humans
/ Original
/ Promoter Regions, Genetic - genetics
/ Protein Isoforms - metabolism
/ Proteins
/ RNA, Long Noncoding - genetics
/ RNA, Long Noncoding - metabolism
/ Transcription, Genetic - drug effects
